Piper Jaffray Starts Bluebird Bio (BLUE) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Pentagon reportedly locked down, hazmat teams responding
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
bluebird bio (BLUE) on Watch after Monday's 32% Surge
June 17, 2014 8:42 AM EDTbluebird bio (NASDAQ: BLUE) is on watch today after gaining 32% on Monday on the back of initial positive clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects at the 19th Annual Congress of the European Hematology... More
